Indicated for: asthma; chronic obstructive pulmonary disease
Substance: beclomethasone + formoterol (bronchodilator + beta-2 adrenergic agonist)
ATC: R03AK08 (Respiratory system | Adrenergics, inhalants | Adrenergics in combination with corticosteroids or other drugs, excl. anticholinergics)
Beclometasone + formoterol is a combination of a corticosteroid and a long-acting beta-agonist used in the treatment of asthma and chronic obstructive pulmonary disease (COPD). Beclometasone reduces airway inflammation, while formoterol relaxes the smooth muscles of the bronchi, improving airflow.
This combination is administered as an inhaler, usually twice daily, as maintenance therapy to prevent symptoms and exacerbations. It is indicated for patients requiring both inflammation control and bronchodilation.
Common side effects include throat irritation, hoarseness, tremors, and palpitations. In rare cases, severe adverse reactions such as paradoxical bronchospasm or hypokalemia may occur. It is important for patients to follow the prescribed dosage and use the inhaler correctly to maximize treatment benefits.
Beclometasone + formoterol is an effective therapeutic option for managing chronic respiratory diseases, contributing to improved quality of life for patients.